Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 19, 2018Abstracts presented add to growing body of FYCOMPA data supporting convulsive seizure freedom, and real-world, long-term safety & efficacy data
Eisai Inc. will present six posters on FYCOMPA® (perampanel) CIII at the American Academy of Neurology (AAN) Annual Meeting in Los Angeles from April 21-27. The poster presentations will include...
-
Mar 30, 2018- First step to making FYCOMPA available for children, underscoring Eisai's commitment to epilepsy care for patients of all ages
Eisai Inc. announced today that it has submitted a supplemental New Drug Application (sNDA) for priority review to the U.S. Food and Drug Administration (FDA) for its antiepileptic drug FYCOMPA®...
-
Mar 7, 2018
Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, "Purdue Pharma") today announced positive topline results from multiple studies of lemborexant,...
-
Feb 15, 2018
Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (marketed as...
-
Feb 5, 2018
Eisai Inc. today announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribulin mesylate (marketed as Halaven® Injection) with dacarbazine in...